221 related articles for article (PubMed ID: 34866279)
1. Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.
Kitamura S; Yanagi T; Maeda T; Ujiie H
Cancer Sci; 2022 Feb; 113(2):802-807. PubMed ID: 34866279
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of cyclin-dependent kinase 4 protein in extramammary Paget's disease.
Urata K; Kajihara I; Myangat TM; Tasaki Y; Otsuka-Maeda S; Sawamura S; Kanazawa-Yamada S; Sakamoto R; Makino K; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Ihn H
J Dermatol; 2019 May; 46(5):444-448. PubMed ID: 30897229
[TBL] [Abstract][Full Text] [Related]
3. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
4. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
5. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease.
Azmahani A; Nakamura Y; Ozawa Y; McNamara KM; Fujimura T; Haga T; Hashimoto A; Aiba S; Sasano H
Hum Pathol; 2015 Nov; 46(11):1662-9. PubMed ID: 26359540
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Otsuka-Maeda S; Mijiddorj MT; Kajihara I; Sakamoto R; Yamada-Kanazawa S; Kanemaru H; Nishimura Y; Sawamura S; Makino K; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
Jpn J Clin Oncol; 2021 Jul; 51(7):1176-1178. PubMed ID: 33912910
[TBL] [Abstract][Full Text] [Related]
8. CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease.
Hashimoto H; Kaku-Ito Y; Oda Y; Ito T
Front Oncol; 2021; 11():710378. PubMed ID: 34395284
[TBL] [Abstract][Full Text] [Related]
9. HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.
Tokuchi K; Maeda T; Kitamura S; Yanagi T; Ujiie H
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884581
[TBL] [Abstract][Full Text] [Related]
10. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
[TBL] [Abstract][Full Text] [Related]
11. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
13. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease.
Aoyagi S; Akiyama M; Shimizu H
J Dermatol Sci; 2008 Jun; 50(3):177-84. PubMed ID: 18248961
[TBL] [Abstract][Full Text] [Related]
14. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
18. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
19. NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target.
Murata M; Ito T; Tanaka Y; Kaku-Ito Y; Furue M
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824340
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients.
Kang Z; Zhang Q; Zhang Q; Li X; Hu T; Xu X; Wu Z; Zhang X; Wang H; Xu J; Xu F; Guan M
Int J Clin Exp Pathol; 2015; 8(10):13233-40. PubMed ID: 26722523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
